cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.3798102.v1
title: Rotated sphere packing designs

description: We propose a new class of space-filling designs called rotated sphere packing designs for computer experiments. The approach starts from the asymptotically optimal positioning of identical balls that covers the unit cube. Properly scaled, rotated, translated and extracted, such designs are excellent in maximin distance criterion, low in discrepancy, good in projective uniformity and thus useful in both prediction and numerical integration purposes. We provide a fast algorithm to construct such designs for any numbers of dimensions and points with R codes available online. Theoretical and numerical results are also provided.
DOI: 10.6084/m9.figshare.3798099
title: The Interatheriinae from the Late Oligocene of Mendoza (Argentina), with comments on some Deseadan Interatheriidae

description: This contribution discusses the interatheriids from Quebrada Fiera, a Late Oligocene locality in the south of Mendoza Province. In addition, the taxonomic status of the Deseadan interatheres <i>Plagiarthrus clivus</i>, <i>Argyrohyrax proavus</i>, <i>Argyrohyrax proavunculus</i>, ?<i>Argyrohyrax acuticostatus</i>, <i>Progaleopithecus fissurelatus</i>, <i>Progaleopithecus tournoueri</i>, and <i>Notohyrax conicus</i> is discussed. We recognise in Quebrada Fiera <i>A. proavus</i> and <i>Progaleopithecus</i> sp. A possible third taxon is represented by one specimen that shows a combination of features that do not permit accurate assignment. These new remains, in combination with a systematic study of Deseadan interatheres, allow for a better definition of each recognised taxon, extended diagnoses, and clarification of some long-standing taxonomic misconceptions. Indeed, the priority of <i>A. proavus</i> over <i>P. clivus</i> is established, and the latter is proposed as a <i>nomen dubium</i>. Associated deciduous and permanent dentition and some limb bones provide new data on the ontogenetic variation and postcranial morphology of <i>Argyrohyrax</i>. Phylogenetic analysis supports the taxonomic determinations and places <i>A. proavus</i> in a basal position with respect to <i>Archaeophylus</i> or <i>Progaleopithecus</i>. Documented fossil records of <i>Argyrohyrax</i> and <i>Progaleopithecus</i> in Mendoza extend the known range to middle latitudes in central west Argentina; these taxa expand the list of mammals from Quebrada Fiera with Patagonian affinities.
DOI: 10.6084/m9.figshare.3798099.v1
title: The Interatheriinae from the Late Oligocene of Mendoza (Argentina), with comments on some Deseadan Interatheriidae

description: This contribution discusses the interatheriids from Quebrada Fiera, a Late Oligocene locality in the south of Mendoza Province. In addition, the taxonomic status of the Deseadan interatheres <i>Plagiarthrus clivus</i>, <i>Argyrohyrax proavus</i>, <i>Argyrohyrax proavunculus</i>, ?<i>Argyrohyrax acuticostatus</i>, <i>Progaleopithecus fissurelatus</i>, <i>Progaleopithecus tournoueri</i>, and <i>Notohyrax conicus</i> is discussed. We recognise in Quebrada Fiera <i>A. proavus</i> and <i>Progaleopithecus</i> sp. A possible third taxon is represented by one specimen that shows a combination of features that do not permit accurate assignment. These new remains, in combination with a systematic study of Deseadan interatheres, allow for a better definition of each recognised taxon, extended diagnoses, and clarification of some long-standing taxonomic misconceptions. Indeed, the priority of <i>A. proavus</i> over <i>P. clivus</i> is established, and the latter is proposed as a <i>nomen dubium</i>. Associated deciduous and permanent dentition and some limb bones provide new data on the ontogenetic variation and postcranial morphology of <i>Argyrohyrax</i>. Phylogenetic analysis supports the taxonomic determinations and places <i>A. proavus</i> in a basal position with respect to <i>Archaeophylus</i> or <i>Progaleopithecus</i>. Documented fossil records of <i>Argyrohyrax</i> and <i>Progaleopithecus</i> in Mendoza extend the known range to middle latitudes in central west Argentina; these taxa expand the list of mammals from Quebrada Fiera with Patagonian affinities.
DOI: 10.6084/m9.figshare.3796620
title: Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry

description: Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry
DOI: 10.6084/m9.figshare.3796620.v2
title: Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry

description: Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry
DOI: 10.6084/m9.figshare.3796620.v1
title: Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry

description: Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry
DOI: 10.6084/m9.figshare.3796452
title: Reaction Times following true contextual change-points

description: Mean baseline-corrected (empirical and simulated) RTs for the 25 trials following true change-points for 124 participants.<br>x.EmpiricalRTs and x.SimulatedRTs are participant x trial from change-point.<br><br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-
DOI: 10.6084/m9.figshare.3796452.v1
title: RTs following true contextual change-points

description: Baseline-corrected RTs (empirical and simulated) for the 25 trials following true change-points are provided for 124 participants.<br>DrugID gives the row-wise drug identifier for each subject where:1 = Placebo2 = DA-3 = ACh-4 = NA-
DOI: 10.6084/m9.figshare.3796452.v2
title: RTs following true contextual change-points

description: Baseline-corrected RTs (empirical and simulated) for the 25 trials following true change-points are provided for 124 participants.<br>DrugID gives the row-wise drug identifier for each subject where:1 = Placebo2 = DA-3 = ACh-4 = NA-
DOI: 10.6084/m9.figshare.3796452.v4
title: Reaction Times following true contextual change-points

description: Mean baseline-corrected (empirical and simulated) RTs for the 25 trials following true change-points for 124 participants.<br>x.EmpiricalRTs and x.SimulatedRTs are participant x trial from change-point.<br><br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-
DOI: 10.6084/m9.figshare.3796452.v3
title: RTs following true contextual change-points

description: Mean baseline-corrected (empirical and simulated) RTs for the 25 trials following true change-points for 124 participants.<br>x.EmpiricalRTs and x.SimulatedRTs are participant x trial from change-point.<br><br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-
DOI: 10.6084/m9.figshare.3796449
title: Simulated logRTs categorised by true transition probabilities

description: Mean simulated and empirical log(RT) data for 124 participants, categorised according to true transition probabilities. Data are organised into four sub-structures for the different drug-groups: x.Placebo, x.DA, x.ACh, and x.NA.<br>Simulated log(RTs) for each participant are the means of 100 runs.<br>x.simulatedlogRTs_mean100runs and x.empiricallogRTa_mean data are participant x true transition probability, where:Column 1 = high true transition probability (p=0.85 or p=0.70)Column 2 = mid true transition probability (p=0.25 or p=0.20)Column 3 = low true transition probability (p=0.05)<br>
DOI: 10.6084/m9.figshare.3796449.v1
title: Simulated logRTs

description: Simulated log(RT) data for 124 participants (organised into Placebo, DA-, ACh- and DA- groups) are the means of 100 runs.<br>Raw log(RTs) are the empirical observations for 124 participants (organised into Placebo, DA-, ACh- and DA- groups).<br>In each case:Column 1 = high true transition probability (p=0.85 or p=0.70)Column 2 = mid true transition probability (p=0.25 or p=0.20)Column 3 = low true transition probability (p=0.05)<br>
DOI: 10.6084/m9.figshare.3796449.v3
title: Simulated logRTs categorised by true transition probabilities

description: Mean simulated and empirical log(RT) data for 124 participants, categorised according to true transition probabilities. Data are organised into four sub-structures for the different drug-groups: x.Placebo, x.DA, x.ACh, and x.NA.<br>Simulated log(RTs) for each participant are the means of 100 runs.<br>x.simulatedlogRTs_mean100runs and x.empiricallogRTa_mean data are participant x true transition probability, where:Column 1 = high true transition probability (p=0.85 or p=0.70)Column 2 = mid true transition probability (p=0.25 or p=0.20)Column 3 = low true transition probability (p=0.05)<br>
DOI: 10.6084/m9.figshare.3796449.v2
title: Simulated logRTs

description: Mean simulated and empirical log(RT) data for 124 participants, categorised according to true transition probabilities. Data are organised into four sub-structures for the different drug-groups: x.Placebo, x.DA, x.ACh, and x.NA.<br>Simulated log(RTs) for each participant are the means of 100 runs.<br>x.simulatedlogRTs_mean100runs and x.empiricallogRTa_mean data are participant x true transition probability, where:Column 1 = high true transition probability (p=0.85 or p=0.70)Column 2 = mid true transition probability (p=0.25 or p=0.20)Column 3 = low true transition probability (p=0.05)<br>
DOI: 10.6084/m9.figshare.3796446
title: Autocorrelations for the residuals between observed logRTs and those predicted by the HGF model

description: Autocorrelations between residuals for 124 participants across 1200 trials. x.residuals are participant x trial.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-
DOI: 10.6084/m9.figshare.3796446.v1
title: Autocorrelations between residuals

description: Autocorrelations between residuals for 124 participants across 1200 trials. x.residuals are participant x trial.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-
DOI: 10.6084/m9.figshare.3796446.v3
title: Autocorrelations for the residuals between observed logRTs and those predicted by the HGF model

description: Autocorrelations between residuals for 124 participants across 1200 trials. x.residuals are participant x trial.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-
DOI: 10.6084/m9.figshare.3796446.v2
title: Autocorrelations for the residuals between observed logRTs and those predicted by the HGF

description: Autocorrelations between residuals for 124 participants across 1200 trials. x.residuals are participant x trial.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-
DOI: 10.6084/m9.figshare.3796443
title: Residuals between observed log(RTs) and those predicted by the HGF model

description: Residuals between observed log(RTs) and those predicted by the HGF for 124 participants across 1200 trials. x.logRTresiduals data are participant x trial.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br><br>
DOI: 10.6084/m9.figshare.3796443.v2
title: Residuals between observed log(RTs) and those predicted by the HGF model

description: Residuals between observed log(RTs) and those predicted by the HGF for 124 participants across 1200 trials. x.logRTresiduals data are participant x trial.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br><br>
DOI: 10.6084/m9.figshare.3796443.v1
title: HGF logRT Residuals

description: Residuals between observed log(RTs) and those predicted by the HGF for 124 participants across 1200 trials. x.logRTresiduals data are participant x trial.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br><br>
DOI: 10.6084/m9.figshare.3796434
title: Correlations between the HGF model parameters

description: Estimated HGF model posteriors for 124 participants.<br>x.DrugID gives the row-wise drug identifier for each participant where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br>x.MeanPosteriorCorrelations and x.BPACorrelations contain correlation matrices for the HGF parameters, where row/column:1 = mu3_02 = sa3_03 = omega4 = theta5 = beta06 = beta17 = beta28 = beta39 = beta410 = zeta<br>Note that Bayesian Parameter Averages (BPAs) are calculated using the function tapas_bayesian_parameter_average in the HGF toolbox (http://www.translationalneuromodeling.org/tapas/).<br>
DOI: 10.6084/m9.figshare.3796434.v2
title: Correlations between the HGF model parameters

description: Estimated HGF model posteriors for 124 participants.<br>x.DrugID gives the row-wise drug identifier for each participant where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br>x.MeanPosteriorCorrelations and x.BPACorrelations contain correlation matrices for the HGF parameters, where row/column:1 = mu3_02 = sa3_03 = omega4 = theta5 = beta06 = beta17 = beta28 = beta39 = beta410 = zeta<br>Note that Bayesian Parameter Averages (BPAs) are calculated using the function tapas_bayesian_parameter_average in the HGF toolbox (http://www.translationalneuromodeling.org/tapas/).<br>
DOI: 10.6084/m9.figshare.3796413
title: Bayesian Model Comparison Results for Three Response Models

description: Posterior Probabilities and Protected Exceedance Probabilities obtained from Bayesian Model Comparison of three alternative Response Models described in Marshall et al.<br>Data are drug-group x response model, where: Drug-group (row) 1 = PlaceboDrug-group (row) 2 = DA-Drug-group (row) 3 = ACh-Drug-group (row) 4 = NA-<br>and<br>Column 1 = Response Model 1Column 2 = Response Model 2Column 3 = Response Model 3
DOI: 10.6084/m9.figshare.3796413.v1
title: Bayesian Model Comparison

description: Posterior Probabilities and Protected Exceedance Probabilities obtained from Bayesian Model Comparison of three alternative Response Models described in Marshall et al.<br>Data are drug-group x response model, where: Drug-group (row) 1 = PlaceboDrug-group (row) 2 = DA-Drug-group (row) 3 = ACh-Drug-group (row) 4 = NA-<br>and<br>Column 1 = Response Model 1Column 2 = Response Model 2Column 3 = Response Model 3
DOI: 10.6084/m9.figshare.3796413.v3
title: Bayesian Model Comparison Results for Three Response Models

description: Posterior Probabilities and Protected Exceedance Probabilities obtained from Bayesian Model Comparison of three alternative Response Models described in Marshall et al.<br>Data are drug-group x response model, where: Drug-group (row) 1 = PlaceboDrug-group (row) 2 = DA-Drug-group (row) 3 = ACh-Drug-group (row) 4 = NA-<br>and<br>Column 1 = Response Model 1Column 2 = Response Model 2Column 3 = Response Model 3
DOI: 10.6084/m9.figshare.3796413.v2
title: Bayesian Model Comparison Results

description: Posterior Probabilities and Protected Exceedance Probabilities obtained from Bayesian Model Comparison of three alternative Response Models described in Marshall et al.<br>Data are drug-group x response model, where: Drug-group (row) 1 = PlaceboDrug-group (row) 2 = DA-Drug-group (row) 3 = ACh-Drug-group (row) 4 = NA-<br>and<br>Column 1 = Response Model 1Column 2 = Response Model 2Column 3 = Response Model 3
DOI: 10.6084/m9.figshare.3796407
title: HGF Model Parameter Estimates for 124 healthy human participants

description: Estimated HGF parameters for 124 participants.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br>x.DeltaAlertness and x.BodyWeight were used as covariates in the analyses.<br>Alpha1 trajectories 30 trials either side of true contextual change-points are provided for the 32 participants from the Placebo group. These trajectories are categorised according to three types of transition matrix switch:1. 0th order to 0th order (x.PlaceboAlpha1_ZeroOrdertoZeroOrder)2. 0th order to 1st order (x.PlaceboAlpha1_ZeroOrdertoFirstOrder)3. 0th order to Alternating (x.PlaceboAlpha1_ZeroOrdertoAlternating)<br>Data are participant x trial from outcome (-30 to 30).
DOI: 10.6084/m9.figshare.3796407.v1
title: Model Parameter Results

description: HGF parameter results for 124 participants.<br>DrugID gives the row-wise drug identifier for each subject where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br>DeltaAlertness and BodyWeight were used as covariates in the analyses.<br>Alpha1 trajectories 30 trials either side of true contextual change-points are provided for the 32 participants from the Placebo group. These trajectories are categorised according to whether the switch of transition matrix is from:1. 0th order to 0th order (3 occurrences)2. 0th order to 1st order (4 occurrences)3. 0th order to Alternating (4 occurrences)<br>The alpha1 data are arranged as follows:subject x occurrence x trial from change point (-30 to 30)
DOI: 10.6084/m9.figshare.3796407.v2
title: Model Parameter Results

description: Estimated HGF parameters for 124 participants.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br>x.DeltaAlertness and x.BodyWeight were used as covariates in the analyses.<br>Alpha1 trajectories 30 trials either side of true contextual change-points are provided for the 32 participants from the Placebo group. These trajectories are categorised according to three types of transition matrix switch:1. 0th order to 0th order (x.PlaceboAlpha1_ZeroOrdertoZeroOrder)2. 0th order to 1st order (x.PlaceboAlpha1_ZeroOrdertoFirstOrder)3. 0th order to Alternating (x.PlaceboAlpha1_ZeroOrdertoAlternating)<br>Data are participant x trial from outcome (-30 to 30).
DOI: 10.6084/m9.figshare.3796407.v4
title: HGF Model Parameter Estimates for 124 healthy human participants

description: Estimated HGF parameters for 124 participants.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br>x.DeltaAlertness and x.BodyWeight were used as covariates in the analyses.<br>Alpha1 trajectories 30 trials either side of true contextual change-points are provided for the 32 participants from the Placebo group. These trajectories are categorised according to three types of transition matrix switch:1. 0th order to 0th order (x.PlaceboAlpha1_ZeroOrdertoZeroOrder)2. 0th order to 1st order (x.PlaceboAlpha1_ZeroOrdertoFirstOrder)3. 0th order to Alternating (x.PlaceboAlpha1_ZeroOrdertoAlternating)<br>Data are participant x trial from outcome (-30 to 30).
DOI: 10.6084/m9.figshare.3796407.v3
title: HGF Model Parameter Results

description: Estimated HGF parameters for 124 participants.<br>x.DrugID gives the row-wise drug identifier for each participant, where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br>x.DeltaAlertness and x.BodyWeight were used as covariates in the analyses.<br>Alpha1 trajectories 30 trials either side of true contextual change-points are provided for the 32 participants from the Placebo group. These trajectories are categorised according to three types of transition matrix switch:1. 0th order to 0th order (x.PlaceboAlpha1_ZeroOrdertoZeroOrder)2. 0th order to 1st order (x.PlaceboAlpha1_ZeroOrdertoFirstOrder)3. 0th order to Alternating (x.PlaceboAlpha1_ZeroOrdertoAlternating)<br>Data are participant x trial from outcome (-30 to 30).
DOI: 10.6084/m9.figshare.3796404
title: Report of the Department of Antiquities, Cyprus (RDAC) - Collective Contents List - 1934-1948, 1963-2010

description: As part of my doctoral studies I have been reviewing several journal titles and one of them has been the Report of the Department of Antiquities, Cyprus (henceforth RDAC). The latter journal is not extensively catalogued, indexed or digitized at the moment, which makes it very difficult for researchers to find articles published there. Therefore, I decided to create a comprehensive list of contents for the RDAC from its first published volume in 1934 to the latest volume published in 2010. In the link below you will find an Excel workbook with a complete listing of the contents of each RDAC volume, full references to each item and some other goodies (article counters - for that you will need to activate Macros, so that some VBA code running in the background gets activated). This project has taken almost two months to bring to completion and now with the consent of the Department of Antiquities, Cyprus is offered under a CC BY-NC-SA (Creative Commons Attribution-Non Commercial-Share Alike) 4.0 International License to all researchers working in the archaeology of Cyprus.
DOI: 10.6084/m9.figshare.3796401
title: Mean logRTs categorised by participant-specific beliefs

description: Mean logRTs for 124 participants categorised by participant-specific beliefs about the true transition probabilities (model parameter mu1hat). x.FiveBeliefCategories data are participant x belief where:<br>Column 1 = mu1hat 0.8-1Column 2 = mu1hat 0.6-0.8Column 3 = mu1hat 0.4-0.6Column 4 = mu1hat 0.2-0.4Column 5 = mu1hat 0-0.2NaN = missing data<br>x.DrugID gives the row-wise drug identifier for each participant where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br>x.DeltaAlertness and x.BodyWeight were used as covariates in the analyses.
DOI: 10.6084/m9.figshare.3796401.v2
title: Mean logRTs categorised by participant-specific beliefs

description: Mean logRTs for 124 participants categorised by participant-specific beliefs about the true transition probabilities (model parameter mu1hat). x.FiveBeliefCategories data are participant x belief where:<br>Column 1 = mu1hat 0.8-1Column 2 = mu1hat 0.6-0.8Column 3 = mu1hat 0.4-0.6Column 4 = mu1hat 0.2-0.4Column 5 = mu1hat 0-0.2NaN = missing data<br>x.DrugID gives the row-wise drug identifier for each participant where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br>x.DeltaAlertness and x.BodyWeight were used as covariates in the analyses.
DOI: 10.6084/m9.figshare.3796401.v1
title: Mean logRTs categorised by model beliefs

description: Mean logRTs for 124 participants are provided across five categories of participant-specific beliefs about the true transition probabilities (mu1hat), where:<br>Column 1 = mu1hat belief = 0.8-1Column 2 = mu1hat belief = 0.6-0.8Column 3 = mu1hat belief = 0.4-0.6Column 4 = mu1hat belief = 0.2-0.4Column 5 = mu1hat belief = 0-0.2NaN = missing data<br>DrugID gives the row-wise drug identifier for each subject where:1 = Placebo2 = DA-3 = ACh-4 = NA-<br>DeltaAlertness and BodyWeight were used as covariates in the analyses.
DOI: 10.6084/m9.figshare.3796362
title: Example mu1hat trajectories for two healthy human participants

description: Example mu1hat trajectories are provided for two example participants:1. Participant 2 from the Placebo group2. Participant 16 from the ACh- group.<br>Data are 1200 x 4 x 4, where trajectories across 1200 trials are provided for each of the 16 possible transitions between consecutive stimuli (arranged in a 4x4 matrix).
DOI: 10.6084/m9.figshare.3796362.v1
title: New draft item

description: Example mu1hat trajectories are provided for two example participants: 1 from the Placebo group and 1 from the ACh- group. Trajectories across 1200 trials are provided for each of the 16 possible transitions between consecutive stimuli (arranged in a 4x4 matrix).
DOI: 10.6084/m9.figshare.3796362.v3
title: Example mu1hat trajectories for two healthy human participants

description: Example mu1hat trajectories are provided for two example participants:1. Participant 2 from the Placebo group2. Participant 16 from the ACh- group.<br>Data are 1200 x 4 x 4, where trajectories across 1200 trials are provided for each of the 16 possible transitions between consecutive stimuli (arranged in a 4x4 matrix).